Roche Hong Kong Limited (2022) – Salween MR43808: A Phase IIIb/IV, Multicenter, Open-Label, Single-Arm Study to Investigate the E�cacy and Safety of Faricimab (Ro6867461) in Patients with Polypoidal Choroidal Vasculopathy [Principal Investigator - Dr Nicholas Fung] Roche Hong Kong Limited (2022) – MR42410: A Phase IIIb, Multicenter, Randomized, Visual Assessor-Masked Study of the E�ectiveness And Safety of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab vs Aflibercept Treat & Extend in Subjects with Neovascular Age-Related Macular Degeneration (DIAGRID) [Principal Investigator - Dr Nicholas Fung] ONL Therapeutics (2022) – ONL1204-GA-001: A Phase 1b Multicenter, Randomized, Controlled, Multi-dose Study of the Safety and Tolerability of ONL1204 Ophthalmic Solution in Patients with Geographic Atrophy (GA) Associated with Agerelated Macular Degeneration (AMD) [Principal Investigator - Dr Nicholas Fung] Ripple Therapeutics (2022) – IBE-814-IVT-1: Evaluation of Safety and E�cacy of the IBE-814 Intravitreal Implant in Patients with Diabetic Macular Oedema and Macular Oedema due to Retinal Vein Occlusion [Principal Investigator - Dr Nicholas Fung] Alcon (2021) – 20K study: comparing the e�ciency and safety of 10K and 20K high speed vitrectomy cu�er [Principal Investigator - Dr Nicholas Fung] Health and Medical Research Fund (2021/22) – Deep Learning Colour Fundus Image Analysis for Triage of Chinese Elderly Patients Presenting with Chronic Vision Loss [Principal Investigator - Dr Kendrick Shih] Health and Medical Research Fund (2021/22) – Developing AI-powered retinal layer segmentation to improve the detection of glaucoma & its progression from wide-field OCT imaging [Principal Investigator - Dr Alexander Lam] 10 Research at HKU Ophthalmology 香港大學眼科學系——研究成果
RkJQdWJsaXNoZXIy Mzg4NDg0